Abstract
Background and AimsThe POISE randomized double-blind (DB) placebo-controlled trial and open label extension (OLE) demonstrated that obeticholic acid (OCA) reduced biomarkers associated with adverse clinical outcomes in patients with primary...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have